Circulating Bile Acids as Biomarkers for Disease Diagnosis and Prevention
Authors:
- 14 November 2022
- journal article
- review article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 108 (2) , 251-270
Abstract
Context: Bile acids (BAs) are pivotal signaling molecules that regulate energy metabolism and inflammation. Recent epidemiological studies have reported specific alterations in circulating BA profiles in certain disease states, including obesity, type 2 diabetes mellitus (T2DM), nonalcoholic fatty liver disease (NAFLD), and Alzheimer disease (AD). In the past decade, breakthroughs have been made regarding the translation of BA profiling into clinical use for disease prediction. In this review, we summarize and synthesize recent data on variation in circulating BA profiles in patients with various diseases to evaluate the value of these biomarkers in human plasma for early diagnosis. Evidence Acquisition: This review is based on a collection of primary and review literature gathered from a PubMed search for BAs, obesity, T2DM, insulin resistance (IR), NAFLD, hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), colon cancer, and AD, among other keywords. Evidence Synthesis: Individuals with obesity, T2DM, HCC, CCA, or AD showed specific alterations in circulating BA profiles. These alterations may have existed long before the initial diagnosis of these diseases. The intricate relationship between obesity, IR, and NAFLD complicates the establishment of clear and independent associations between BA profiles and nonalcoholic steatohepatitis. Alterations in the levels of total BAs and several BA species were seen across the entire spectrum of NAFLD, demonstrating significant increases with the worsening of histological features. Conclusions: Aberrant circulating BA profiles are an early event in the onset and progression of obesity, T2DM, HCC, and AD. The pleiotropic effects of BAs explain these broad connections. Circulating BA profiles could provide a basis for the development of biomarkers for the diagnosis and prevention of a wide range of diseases.Keywords
Funding Information
- Natural Science Foundation of Liaoning Province (2022-MS-182)
This publication has 118 references indexed in Scilit:
- Metabolomics Study of Stepwise Hepatocarcinogenesis From the Model Rats to Patients: Potential Biomarkers Effective for Small Hepatocellular Carcinoma DiagnosisMolecular & Cellular Proteomics, 2012
- Serum and Urine Metabolite Profiling Reveals Potential Biomarkers of Human Hepatocellular CarcinomaMolecular & Cellular Proteomics, 2011
- Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitisEuropean Journal of Gastroenterology & Hepatology, 2011
- Plasma metabolomic profile in nonalcoholic fatty liver diseaseMetabolism, 2011
- Fasting plasma chenodeoxycholic acid and cholic acid concentrations are inversely correlated with insulin sensitivity in adultsNutrition & Metabolism, 2011
- The relationship between postprandial bile acid concentration, GLP‐1, PYY and ghrelinClinical Endocrinology, 2010
- Improved Glycemic Control with Colesevelam Treatment in Patients with Type 2 Diabetes Is Not Directly Associated with Changes in Bile Acid MetabolismHepatology, 2010
- OST alpha-OST beta: a key membrane transporter of bile acids and conjugated steroidsFrontiers in Bioscience-Landmark, 2009
- Spontaneous hepatocarcinogenesis in farnesoid X receptor-null miceCarcinogenesis, 2006
- The Farnesoid X Receptor Modulates Hepatic Carbohydrate Metabolism during the Fasting-Refeeding TransitionJournal of Biological Chemistry, 2005